Cavitation Technologies, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cavitation Technologies, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $203.0K | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $1.36M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $433.0K | Sep 30, 2024 |
| FY2021 | Jun 30, 2021 | $558.0K | Oct 13, 2021 |
| FY2021 | Jun 30, 2020 | $1.66M | Oct 13, 2021 |
| FY2020 | Jun 30, 2019 | $1.09M | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | $1.30M | Oct 15, 2019 |
| FY2018 | Jun 30, 2017 | $1.90M | Oct 15, 2018 |
| FY2017 | Jun 30, 2016 | $1.80M | Nov 3, 2017 |
| FY2016 | Jun 30, 2015 | $489.3K | Oct 13, 2016 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Jun 30, 2014 | $1.86M | Oct 14, 2014 |
| FY2014 | Jun 30, 2013 | $1.26M | Oct 14, 2014 |
| FY2013 | Jun 30, 2012 | $187.2K | Oct 28, 2013 |
| FY2012 | Jun 30, 2011 | $589.9K | Oct 15, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $165.0K | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $1.21M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $312.0K | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $1.62M | Oct 3, 2023 |
| FY2022 | Jun 30, 2021 | $538.0K | Feb 10, 2023 |
| FY2021 | Jun 30, 2020 | $1.62M | Oct 13, 2021 |
| FY2020 | Jun 30, 2019 | $1.02M | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | $1.18M | Oct 15, 2019 |
| FY2018 | Jun 30, 2017 | $1.80M | Oct 15, 2018 |
| FY2017 | Jun 30, 2016 | $1.68M | Nov 3, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($113.0K) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $439.0K | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($2.04M) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($619.0K) | Oct 3, 2023 |
| FY2022 | Jun 30, 2021 | ($649.0K) | Feb 10, 2023 |
| FY2021 | Jun 30, 2020 | $128.0K | Oct 13, 2021 |
| FY2020 | Jun 30, 2019 | ($723.0K) | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | ($250.0K) | Oct 15, 2019 |
| FY2018 | Jun 30, 2017 | ($233.0K) | Oct 15, 2018 |
| FY2017 | Jun 30, 2016 | $432.8K | Nov 3, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($987.0K) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $438.0K | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($886.0K) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($299.0K) | Oct 3, 2023 |
| FY2022 | Jun 30, 2021 | ($747.0K) | Feb 10, 2023 |
| FY2021 | Jun 30, 2020 | $136.0K | Oct 13, 2021 |
| FY2020 | Jun 30, 2019 | ($723.0K) | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | ($351.0K) | Oct 15, 2019 |
| FY2018 | Jun 30, 2017 | ($232.0K) | Oct 15, 2018 |
| FY2014 | Jun 30, 2014 | ($749.4K) | Oct 14, 2014 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $95.0K | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $61.0K | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $3.0K | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $17.0K | Oct 3, 2023 |
| FY2022 | Jun 30, 2021 | $21.0K | Feb 10, 2023 |
| FY2021 | Jun 30, 2020 | $18.0K | Oct 13, 2021 |
| FY2020 | Jun 30, 2019 | $25.0K | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | $25.0K | Oct 15, 2019 |
| FY2018 | Jun 30, 2017 | $27.0K | Oct 15, 2018 |
| FY2017 | Jun 30, 2016 | $29.4K | Nov 3, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($806.0K) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $172.0K | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($423.0K) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($484.0K) | Oct 3, 2023 |
| FY2022 | Jun 30, 2021 | ($250.0K) | Feb 10, 2023 |
| FY2021 | Jun 30, 2020 | $56.0K | Oct 13, 2021 |
| FY2020 | Jun 30, 2019 | ($280.0K) | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | $396.0K | Oct 15, 2019 |
| FY2018 | Jun 30, 2017 | ($52.0K) | Oct 15, 2018 |
| FY2017 | Jun 30, 2016 | ($759.6K) | Nov 3, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Jun 30, 2021 | $128.0K | Feb 10, 2023 |
| FY2021 | Jun 30, 2020 | $50.0K | Oct 13, 2021 |
| FY2020 | Jun 30, 2019 | $16.0K | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | $0 | Oct 15, 2019 |
| FY2018 | Jun 30, 2017 | $56.0K | Oct 15, 2018 |
| FY2017 | Jun 30, 2016 | $61.6K | Nov 3, 2017 |
| FY2016 | Jun 30, 2015 | $22.8K | Oct 13, 2016 |
| FY2015 | Jun 30, 2014 | ($43.3K) | Oct 13, 2015 |
| FY2014 | Jun 30, 2013 | $90.1K | Oct 14, 2014 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $297.0K | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $248.0K | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $143.0K | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $1.87M | Oct 3, 2023 |
| FY2022 | Jun 30, 2021 | $1.83M | Feb 10, 2023 |
| FY2021 | Jun 30, 2020 | $1.30M | Oct 13, 2021 |
| FY2020 | Jun 30, 2019 | $1.02M | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | $1.08M | Oct 15, 2019 |
| FY2018 | Jun 30, 2017 | $930.0K | Oct 15, 2018 |
| FY2017 | Jun 30, 2016 | $959.7K | Nov 3, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $228.0K | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $728.0K | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $1.06M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $835.0K | Oct 3, 2023 |
| FY2022 | Jun 30, 2021 | $2.24M | Feb 10, 2023 |
| FY2021 | Jun 30, 2020 | $1.79M | Oct 13, 2021 |
| FY2020 | Jun 30, 2019 | $1.84M | Oct 13, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $69.0K | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($480.0K) | Sep 29, 2025 |
| FY2025 | Jun 30, 2023 | ($919.0K) | Sep 29, 2025 |
| FY2024 | Jun 30, 2022 | $1.04M | Sep 30, 2024 |
| FY2023 | Jun 30, 2021 | ($411.0K) | Oct 3, 2023 |
| FY2022 | Jun 30, 2020 | ($490.0K) | Feb 10, 2023 |
| FY2021 | Jun 30, 2019 | ($819.0K) | Oct 13, 2021 |
| FY2020 | Jun 30, 2018 | ($545.0K) | Oct 13, 2020 |
| FY2019 | Jun 30, 2017 | ($311.0K) | Oct 15, 2019 |
| FY2018 | Jun 30, 2016 | ($643.0K) | Oct 15, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($26.96M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($26.85M) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($27.29M) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($25.25M) | Oct 3, 2023 |
| FY2022 | Jun 30, 2021 | ($24.63M) | Feb 10, 2023 |
| FY2021 | Jun 30, 2020 | ($23.98M) | Oct 13, 2021 |
| FY2020 | Jun 30, 2019 | ($24.11M) | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | ($23.38M) | Oct 15, 2019 |
| FY2018 | Jun 30, 2017 | ($23.13M) | Oct 15, 2018 |
| FY2017 | Jun 30, 2016 | ($22.90M) | Nov 3, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $249.0K | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $179.0K | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $18.0K | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $441.0K | Oct 3, 2023 |
| FY2022 | Jun 30, 2021 | $1.36M | Feb 10, 2023 |
| FY2021 | Jun 30, 2020 | $759.0K | Oct 13, 2021 |
| FY2021 | Jun 30, 2019 | $649.0K | Oct 13, 2021 |
| FY2020 | Jun 30, 2018 | $945.0K | Oct 13, 2020 |
| FY2019 | Jun 30, 2017 | $549.0K | Oct 15, 2019 |
| FY2018 | Jun 30, 2016 | $657.0K | Oct 15, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $135.0K | Sep 29, 2025 |
| FY2024 | Jun 30, 2024 | $139.0K | Sep 30, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Oct 3, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Feb 10, 2023 |
| FY2014 | Jun 30, 2014 | 0 | Oct 14, 2014 |
| FY2014 | Jun 30, 2013 | 0 | Oct 14, 2014 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Oct 3, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Feb 10, 2023 |
| FY2014 | Jun 30, 2014 | 0 | Oct 14, 2014 |
| FY2014 | Jun 30, 2013 | 0 | Oct 14, 2014 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 289.16M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | 284.29M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | 284.29M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | 276.70M | Oct 3, 2023 |
| FY2022 | Jun 30, 2021 | 208.27M | Feb 10, 2023 |
| FY2021 | Jun 30, 2020 | 197.00M | Oct 13, 2021 |
| FY2020 | Jun 30, 2019 | 197.00M | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | 197.00M | Oct 15, 2019 |
| FY2018 | Jun 30, 2017 | 196.80M | Oct 15, 2018 |
| FY2017 | Jun 30, 2016 | 194.00M | Nov 3, 2017 |